CNTN
Canton StrategicCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The balance sheet was transformed by the November 2025 financing, 2025 year-end CC fair value was about $501.8 million, and management has paired treasury exposure with validator and governance roles that could create differentiated access if Canton adoption keeps rising [#10-K-2026-03-31].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +19.3.
What can break
Additional capital raises or ATM usage could fund strategy expansion but dilute existing holders.
Momentum
24
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.80 · Bull $5.50 · Bear $2.10
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $5.00
Why
Momentum24 · Δ7d -7.9
Value41 · Δ7d +0.1
Sentiment100 · Δ7d +19.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
24
34% active weight
Current posture
7d trendImproving
Δ7d
-7.9
Δ21d
+14.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendImproving
Δ7d
+19.3
Δ21d
+6.5
Why this grade
Composite grade C. Momentum 24.1 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$165.44M
Beta
1.43
Shares Out
35.04M
P/E (TTM) · Derived
-0.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.82
Rev YoY
-
EPS YoY
+86.3%
Gross Margin
-
Op Margin
-
Net Debt
-$3.56M
Current Ratio
4.98
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology